Tetracyclines increase the survival of NSCLC patients treated with EGFR TKIs: a retrospective nationwide registry study

Tetracyclines increase the survival of NSCLC patients treated with EGFR TKIs: a retrospective nationwide registry study

Background With the first and second-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), clinical benefit and rash correlate together. EGFR TKI-induced rash can be alleviated with tetracyclines, but it is unknown whether the use of tetracyclines can increase the sur...

Full description

Bibliographic Details
Main Authors:	Martti Arffman, Sanna Iivanainen, Jussi Pekka Koivunen, Virve Alanen
Format:	Article
Language:	English
Published:	Elsevier 2020-10-01
Series:	ESMO Open
Online Access:	https://esmoopen.bmj.com/content/5/5/e000864.full

Similar Items

Combination of EGFR-TKIs with chemotherapy versus chemotherapy or EGFR-TKIs alone in advanced NSCLC patients with EGFR mutation
by: Wen M, et al.
Published: (2018-11-01)

Elevated CRP levels indicate poor progression-free and overall survival on cancer patients treated with PD-1 inhibitors
by: Sanna Iivanainen, et al.
Published: (2019-07-01)

Review of EGFR TKIs in metastatic NSCLC, including ongoing trials
by: Barbara eMelosky
Published: (2014-09-01)

Association of Rare Immune-Related Adverse Events to Survival in Advanced Cancer Patients Treated with Immune Checkpoint Inhibitors: A Real-World Single-Center Cohort Study
by: Saara Kuusisalo, et al.
Published: (2022-05-01)

Dynamic Evaluation of Circulating miRNA Profile in <i>EGFR</i>-Mutated NSCLC Patients Treated with EGFR-TKIs
by: Alessandro Leonetti, et al.
Published: (2021-06-01)

PD-L1 expression and its effect on clinical outcomes of EGFR-mutant NSCLC patients treated with EGFR-TKIs
by: Yuchen Bai, et al.
Published: (2018-12-01)

Bevacizumab Combined with Continuation of EGFR-TKIs in NSCLC Beyond Gradual Progression
by: Xu Z, et al.
Published: (2022-06-01)

Chinese Medicine Combined With EGFR-TKIs Prolongs Progression-Free Survival and Overall Survival of Non-small Cell Lung Cancer (NSCLC) Patients Harboring EGFR Mutations, Compared With the Use of TKIs Alone
by: Yujia Wang, et al.
Published: (2021-06-01)

PET/CT Radiomic Features: A Potential Biomarker for EGFR Mutation Status and Survival Outcome Prediction in NSCLC Patients Treated With TKIs
by: Liping Yang, et al.
Published: (2022-06-01)

Re-Treatment with EGFR-TKIs in NSCLC Patients Who Developed Acquired Resistance
by: Wen-Shuo Wu, et al.
Published: (2014-06-01)

The prospect of combination therapies with the third-generation EGFR-TKIs to overcome the resistance in NSCLC
by: Shiyu Li, et al.
Published: (2022-12-01)

Phosphorylated EGFR expression may predict outcome of EGFR-TKIs therapy for the advanced NSCLC patients with wild-type EGFR
by: Wang Fen, et al.
Published: (2012-08-01)

Management of Toxicities in Metastatic NSCLC Related to Anti-Lung Cancer Therapies with EGFR-TKIs
by: Barbara eMelosky, et al.
Published: (2014-09-01)

Primary resistance to first-generation EGFR-TKIs induced by MDM2 amplification in NSCLC
by: Dantong Sun, et al.
Published: (2020-07-01)

Beyond disease-progression: Clinical outcomes after EGFR-TKIs in a cohort of EGFR mutated NSCLC patients.
by: Roxana Alina Tudor, et al.
Published: (2017-01-01)

The role of EGFR‐TKIs as adjuvant therapy in EGFR mutation‐positive early‐stage NSCLC: A meta‐analysis
by: Chutong Lin, et al.
Published: (2021-04-01)

Concomitant Mutations in EGFR 19Del/L858R Mutation and Their Association with Response to EGFR-TKIs in NSCLC Patients
by: Liang H, et al.
Published: (2020-09-01)

Efficacy of EGFR‐TKIs with or without upfront brain radiotherapy for EGFR‐mutant NSCLC patients with central nervous system metastases
by: Yu Saida, et al.
Published: (2019-11-01)

Advances in ICIs Therapy after TKIs Resistance in Patients with EGFR Mutant NSCLC: A Review
by: Ran CHEN, et al.
Published: (2022-08-01)

Combination of EGFR-TKIs and chemotherapy as first-line therapy for advanced NSCLC: a meta-analysis.
by: Pu-Yun OuYang, et al.
Published: (2013-01-01)

Challenges of EGFR-TKIs in NSCLC and the potential role of herbs and active compounds: From mechanism to clinical practice
by: Xiaotong Song, et al.
Published: (2023-04-01)

The Efficacy of Synchronous Combination of Chemotherapy and EGFR TKIs for the First-Line Treatment of NSCLC: A Systematic Analysis.
by: Han Yan, et al.
Published: (2015-01-01)

Prognostic Factors in Lung Adenocarcinoma with Bone Metastasis Treated with EGFR-TKIs
by: Tzu-Hsuan Chiu, et al.
Published: (2021-09-01)

Establishment of prognostic nomograms for predicting the progression free survival of EGFR‐sensitizing mutation, advanced lung cancer patients treated with EGFR‐TKIs
by: Xinyang Du, et al.
Published: (2022-05-01)

Cholesterol promotes EGFR-TKIs resistance in NSCLC by inducing EGFR/Src/Erk/SP1 signaling-mediated ERRα re-expression
by: Zhenzhen Pan, et al.
Published: (2022-03-01)

Concomitant genetic alterations having greater impact on the clinical benefit of EGFR‐TKIs in EGFR‐mutant advanced NSCLC than BIM deletion polymorphism
by: Si‐Yang Liu, et al.
Published: (2020-03-01)

EGFR-TKIs resistance via EGFR-independent signaling pathways
by: Qian Liu, et al.
Published: (2018-02-01)

The Predictive Value of EGFR Status in Non-small Cell Lung Cancer Patients Treated with EGFR-TKIs
by: Jun CHEN, et al.
Published: (2010-04-01)

Efficacy and Safety of Radiotherapy Plus EGFR-TKIs in NSCLC Patients with Brain Metastases: A Meta-Analysis of Published Data
by: Xueyan Wang, et al.
Published: (2018-10-01)

Thick-wall cavity predicts worse progression-free survival in lung adenocarcinoma treated with first-line EGFR-TKIs
by: Fei Zhou, et al.
Published: (2018-10-01)

The combination of fibrinogen concentrations and the platelet-to-lymphocyte ratio predicts survival in patients with advanced lung adenocarcinoma treated with EGFR-TKIs
by: Qiong He, et al.
Published: (2021-04-01)

Research Progress on the Combination Therapy of EGFR-TKIs and Metformin  in Acquired Resistance to EGFR-TKIs in Non-small Cell Lung Cancer
by: Jiamin WANG, et al.
Published: (2023-11-01)

Metformin Prolongs Survival in Type 2 Diabetes Lung Cancer Patients With EGFR-TKIs
by: Ming-Szu Hung MD, PhD, et al.
Published: (2019-08-01)

Impact of minocycline on outcomes of EGFR-mutant non-small cell lung cancer patients treated with EGFR-TKIs
by: Mari Tone, et al.
Published: (2023-05-01)

The impact of different first-line EGFR-TKIs on the clinical outcome of sequential osimertinib treatment in advanced NSCLC with secondary T790M
by: Yen-Hsiang Huang, et al.
Published: (2021-06-01)

A Real-world Study on the Expression Characteristics of PD-L1 in Patients  with Advanced EGFR Positive NSCLC and Its Relationship with the  Therapeutic Efficacy of EGFR-TKIs
by: Ran CHEN, et al.
Published: (2023-03-01)

The prognosis of TP53 and EGFR co-mutation in patients with advanced lung adenocarcinoma and intracranial metastasis treated with EGFR-TKIs
by: Weiguo Gu, et al.
Published: (2024-02-01)

EGFR‐plasma mutations in prognosis for non‐small cell lung cancer treated with EGFR TKIs: A meta‐analysis
by: Thang Thanh Phan, et al.
Published: (2022-08-01)

Effects of EGFR Gene Polymorphisms on Efficacy and Prognosis  in Advanced Non-small Cell Lung Cancer Treated with EGFR-TKIs
by: Liangshan DA, et al.
Published: (2013-03-01)

Patients With Short PFS to EGFR-TKIs Predicted Better Response to Subsequent Anti-PD-1/PD-L1 Based Immunotherapy in EGFR Common Mutation NSCLC
by: Sangtian Liu, et al.
Published: (2021-03-01)